CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Innovacell Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Innovacell Inc
5F
Meguro Villa Garden, 3-5-11, Kamiosaki
Phone: +81 365554437p:+81 365554437 SHINAGAWA-KU, TKY  141-0021  Japan Ticker: 504A504A
Business Summary
Innovacell Inc a Japan-based company develops and manufactures regenerative medicine products targeting fecal and urinary incontinence. The Company operates through a single segment named Cell Therapy and Regenerative Medicine Research and Development. Its business model is a global aggregation model, where it searches for and discovers promising drug and medical device candidates worldwide, incorporates them into its pipeline for development, and commercializes them in the global market. The Company focuses its research and development on a pipeline consisting of cell therapy products using human cells. Currently, it is advancing three pipelines targeting urge fecal incontinence (ICEF15), passive fecal incontinence (ICEF16), and stress urinary incontinence (ICES13).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024-----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Representative Director NovikKorin
Co-Chief Executive Officer, Director JasonSegar

General Information
Number of Employees: 48 (As of 11/30/2025)
Outstanding Shares: 33,335,702 (As of 9/30/2025)
Stock Exchange: TYO
Fax Number: +81 365554436


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, February 18, 2026